Search results
Results from the WOW.Com Content Network
In medicine, the Comorbidity–polypharmacy score (CPS) is a measure of overall severity of comorbidities. [1] It is defined as the simple sum of the number of known comorbidities (concurrent conditions) and pre-admission medications taken by the patient ( polypharmacy ), as a surrogate for the “intensity” of the comorbidities.
In July 2019, the US FDA approved pembrolizumab for patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus (ESCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥ 10), as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy. [24]
Conventional CT and MRI should be performed with cuts of 10 mm or less in slice thickness contiguously. Spiral CT should be performed using a 5 mm contiguous reconstruction algorithm. This applies to tumors of the chest, abdomen and pelvis. Head and neck tumors and those of extremities usually require specific protocols.
Tumors may be graded on four-tier, three-tier, or two-tier scales, depending on the institution and the tumor type. The histologic tumor grade score along with the metastatic (whole-body-level cancer-spread) staging are used to evaluate each specific cancer patient, develop their individual treatment strategy and to predict their prognosis.
A score of zero means that no comorbidities were found; the higher the score, the higher the predicted mortality rate is. [2] [3] For a physician, this score is helpful in deciding how aggressively to treat a condition. It is one of the most widely used scoring system for comorbidities. [4]
For example, if the primary tumor grade was 2 and the secondary tumor grade was 3 but some cells were found to be grade 4, the Gleason score would be 2+4=6. This is a slight change from the pre-2005 Gleason system where the second number was the secondary grade (i.e., the grade of the second-most common cell line pattern).
A score of 1 is assigned to a benign test result, 2 applies to a suspicious test result, and 3 applies to a malignant result. The sum of the scores of all three procedures is the triple test score. If the total summed score from the three tests is 3 to 4 then the diagnosis is most likely benign. A total summed score of 5 is considered suspicious.
These cancer characteristics are described as the size of the tumor (T), whether or not the tumor has spread to the lymph nodes (N) in the armpits, neck, and inside the chest, and whether the tumor has metastasized (M) (i.e. spread to a more distant part of the body). Larger size, nodal spread, and metastasis have a larger stage number and a ...